Home » Newsletters » BioWorld Science

BioWorld Science

April 17, 2019

View Archived Issues

Preventing drug tolerance to forestall resistance

New candidate drug for visceral leishmaniasis

IL-7 receptor plays role in severe IBD

Wave Life Sciences presents phase I data and updates on development of suvodirsen

Gilead and insitro enter strategic collaboration to discover and develop new therapies for NASH

Biomica initiates preclinical studies in immuno-oncology program

Bromodomain inhibitors reported in Medshine Discovery patent

Shanghai Synergy Pharmaceutical Sciences, Zhejiang Huahai Pharmaceutical patent JAK inhibitors

Pohang University of Science and Technology and Seoul National University develop NS5A inhibitors

Traf3ip3 as a potential new marker of skeletal muscle atrophy

BP-1003 shows promising activity in PDAC PDX models

Preclinical characterization of novel anti-VISTA antibody for the treatment of cancer

Discovery and characterization of a novel BCL6 inhibitor, OICR-10268

Safety and immunogenicity of ChAdOx1 Chik vaccine in healthy adult volunteers

RTD-1 shows promising preclinical results in mouse model of cystic fibrosis

Phase I/IIa trial of antibody-inducing peptide FPP-003 begins in Australia

Entasis Therapeutics identifies novel series of PBP3 inhibitors for P. aeruginosa infections

Positive results presented from phase II/III TAZPOWER study of elamipretide

Otsuka Pharmaceutical initiates two phase III studies of OPA-15406 ointment

CTT-1403 enters phase I development for metastatic castration-resistant prostate cancer

Zydus Cadila announces phase III study of desidustat

"Protein intron" delivers selective antibiotic

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...